MARAGANORE JOHN 4

What Happened

• John Maraganore, a director of Rapport Therapeutics, received a derivative award on 2026-06-10 for 15,200 shares (reported as an award/acquisition, code A). The filing lists an acquisition price of $0.00, so the reported immediate cash value is $0. This was a grant of a derivative award (shares/options that vest later), not an open-market purchase or sale.

Key Details

• Transaction date and type: 2026-06-10, Award/Grant (Form 4 code A).
• Quantity and price: 15,200 underlying shares; acquisition price reported $0.00 (total reported value $0).
• Vesting: Per the filing footnote, the shares underlying this option vest on the earlier of (i) June 10, 2027 or (ii) the date of the next Annual Meeting of stockholders, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing summary.
• Timeliness: Reported and filed on 2026-06-10 (appears timely); no 10b5-1 plan or tax-withholding items noted in this filing.

Context

• This is a standard director compensation award (a deferred, derivative grant that vests over time). It does not reflect an immediate purchase or sale of shares and should be interpreted as a grant that may convert into stock if vesting conditions are met. As always, grants to directors are common and do not by themselves indicate the director’s trading intent.